Studies have shown that two doses have been successfully applied
Public Health England (PHE) said on Thursday that the two doses of Covid-19 vaccine from Oxford and AstraZeneca are 85% to 90% effective against symptomatic diseases.
According to Reuters, the UK’s recorded pandemic mortality rate is one of the worst in the world, but it is also one of the countries with the fastest distribution of Covid-19 vaccines, producing a large amount of vaccine use data under actual conditions.
In the weekly monitoring report, the agency pointed out that the estimated efficacy of the AstraZeneca vaccine developed by Oxford University is 89% compared with unvaccinated people.
This number is compared with the estimated 90% efficacy of the Pfizer/BioNTech vaccine against symptomatic diseases.
Nadhim, Minister of Vaccines. Zahawi said: “This new data highlights the incredible impact that two doses of the vaccine can have because the second dose of Oxford/AstraZeneca vaccine can provide up to 90% protection.”
PHE said that the effectiveness of the vaccine has “decreased slightly” starting ten weeks after the first dose. The UK extended the dose interval to 12 weeks, although Pfizer warned that there is no evidence of efficacy beyond the three-week interval used in the trial.
Last week, the United Kingdom shortened the interval for people over 50 to 8 weeks in order to provide the most vulnerable people with the greatest protection from the concerns of the B.1.617.2 variant that was first discovered in India.
The United Kingdom began to distribute vaccines produced by Pfizer and AstraZeneca in December and January respectively, and in April it also began to distribute Moderna vaccines.
PHE also estimates that as of May 9, the Covid-19 vaccine program has avoided 13,000 deaths of people over 60 years old overall, and has ensured that 39,100 people over 65 years old do not need treatment due to Covid-19.